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Objectives The purpose of this study was to quantitatively examine the association of patient- and trial-specific factors with
participation in cardiovascular randomized clinical trials.
Background Randomized clinical trials are central to evidenced-based medicine, but low patient participation rates and po-
tentially modifiable barriers are not well understood.
Methods At a large U.S. academic health system, we examined screening logs from December 1, 2005, to February 28,
2011, from 15 cardiovascular randomized clinical trials. We identified 655 patients who were screened and po-
tentially eligible for participation in at least 1 trial. We used multivariable Poisson regression to quantify the risk
of not participating in a trial associated with patient- and trial-specific factors.
Results The median age was 63 years (interquartile range: 54 to 72), 35% were women, and the median Charlson Index was
2 (interquartile range: 1 to 5). Forty-two percent of patients did not participate in a trial. In multivariable regression
(C-Index 0.85), trial-specific factors strongly associated with not participating included intensive trial-related testing
(relative risk [RR]: 1.89; 95% confidence interval [CI]: 1.63 to 2.20) and anticipated trial participation 6 months
(RR: 4.10; 95% CI: 2.30 to 7.29). Patient-specific factors associated with not participating included older age (RR:
1.23; 95% CI: 1.11 to 1.36, per 10-year increase if age 65 years), out-of-state residence (RR: 1.26; 95% CI: 1.04 to
1.54), and female sex (RR: 1.17; 95% CI: 1.01 to 1.35). Race was not associated with participation.
Conclusions While patient-specific factors were associated with not participating in cardiovascular trials, longer trial duration
and intensive trial-related testing were most strongly associated with risk for patients not participating. Innova-
tive trial designs fostering convenience may most enhance trial participation. (J Am Coll Cardiol 2013;61:
762–9) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.046Randomized clinical trials (RCTs) are central to evidence-
based medicine. Successful RCTs require efficient recruit-
ment of adequately sized study populations that are repre-
sentative of contemporary clinical practice. However,
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2012, accepted October 23, 2012.patient recruitment is a widespread challenge across RCTs,
particularly among cardiovascular RCTs conducted in the
United States, and there is increasing reliance on enrollment
abroad (1–4). Beyond low overall enrollment, under-
representation of certain groups of patients from the com-
munity threatens the generalizability of RCTs (5–14).
See page 770
The developing crisis in RCT participation prompted a
recent National Heart, Blood, and Lung Institute workshop
on strategies for recruitment, from which several themes
emerged, including the role of health care professionals as
gatekeepers (15). Complementing these important initia-
tives, further investigation is needed to identify the most
important barriers to patient participation in RCTs that can
be potentially modified in future RCT designs and recruit-
ment efforts. We quantitatively examined the association of
patient- and trial-specific factors with patient participation
in RCTs in a consecutive sample of patients who were
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1 cardiovascular RCT at a tertiary medical center.
Methods
Study population and data collection. We examined
screening logs from December 1, 2005, to February 28,
2011, at Duke University Medical Center (Durham, North
Carolina), a high-volume tertiary academic health system in
the southeastern United States. Screening logs of patients
considered for RCT participation were routinely maintained
to monitor for bias in selection of subjects for a RCT by
investigators, the institution, and sponsors. Screening logs
contained data on patients’ sociodemographics, RCT eligi-
bilities, and enrollment outcomes. If a patient considered for
participation did not enroll, the primary reason for decline
was documented as specifically as possible. Where possible,
reasons were determined directly by patient report, while
other reasons, including altered mental status, clinical in-
stability, concern for nonadherence or substance abuse, and
provider decline were based on discussion with clinical
providers, review of the medical chart, and/or interview with
the patient or the patient’s family.
Screening logs were available for 15 ongoing or com-
pleted RCTs (16–30). Table 1 summarizes the designs of
each of these trials and displays study features that were
typically discussed with potential participants during in-
formed consent. The targeted populations in these mostly
phase III and IV RCTs reflected a range of clinical diagnoses,
Trial CharacteristicsTable 1 Trial Characteristics
Trial (Ref. #) NCT ID Year Pop. Phase Intervention
APPRAISE-2 (16) 00831441 2009 ACS III PO anticoagulant
ASCEND-HF (17) 00475852 2007 ADHF III IV diuretic
ATMOSPHERE (18) 00853658 2009 sHF III PO renin inhibitor
CARRESS (19) 00608491 2008 ADHF III Ultrafiltration
DOSE (20) 00577135 2008 ADHF III IV furosemide
EXACT-HF (21) 00987415 2010 sHF IV PO XO inhibitor
IMPROVE-IT (22) 00202878 2005 ACS III PO lipid lowering
RED-HF (23) 00358215 2006 sHF III SC epoetin
RELAX (24) 00763867 2008 HF-PEF III PO vasodilator
REVEAL (25) 00378352 2006 STEMI II SC epoetin
ROSE-AHF (26) 01132846 2010 ADHF IV IV pressor and
diuretic
SOLSTICE (27) 00910962 2009 NSTEMI II PO anti-inflam
STABILITY (28) 00799903 2008 CAD III PO anti-inflam
TRACER (29) 00527943 2007 NSTEMI III PO anticoagulant
TRA-Ocular (30) 00617123 2010 Athero III PO anticoagulant
*Recruitment setting. †More than 6 months of anticipated duration of patient participation. ‡$2
magnetic resonance imaging, retinal examinations requiring extended study visits, or peak oxyge
ACS  acute coronary syndrome; ADHF  acute decompensated heart failure; anti-inflam  ant
Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; Athero  atheroscleros
artery disease; CARRESS  Cardiorenal Rescue Study in Acute Decompensated Heart Failure; Cr
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients; exam  examination; G  g
IMPROVE-IT  Improved Reduction of Outcomes: Vytorin Efficacy International Trial; I  industry; IV
trial identifier; NSTEMI  non–ST-segment elevation myocardial infarction; O  outpatient clinic; p
Alfa in Heart Failure; RELAX  Phosphodiesterase-5 Inhibition to Improve Clinical Status and E
Remodeling With Erythropoietin After Large Myocardial Infarction; ROSE-AHF  Renal Optimizatio
Study of Losmapimod Treatment on Inflammation and Infarct Size; STABILITY  Stabilization of
infarction; UO  urine output; TRACER  Thrombin Receptor Antagonist for Clinical Event Reduction in Acu
With Atherosclerosis; XO  xanthine oxidase; Year  year of trial start.including systolic heart failure,
heart failure with preserved ejec-
tion fraction, acute coronary syn-
dromes, stable coronary disease,
and patients with cardiovascular
risk factors.
We identified 667 patients who were considered poten-
tially eligible for participation in at least 1 cardiovascular
RCT after an initial screen against protocol-defined medical
inclusion and exclusion criteria. Some RCTs explicitly
identified an inability to follow the protocol as an exclusion
criterion; however, this assessment may entail subjective
determination, its importance varies based on trial
follow-up requirements, and it is not well understood to
what extent this type of exclusion contributes to participa-
tion outcomes. Therefore, we specifically captured informa-
tion on this group, but did not consider this a reason for
exclusion from the primary analyses of our study. We did
exclude 12 patients with a language barrier because these
patients were systematically excluded from RCTs at our
institution due to the lack of availability of bilingual trial
personnel as well as native language consent forms and
other trial materials. Therefore, 655 patients were in-
cluded in our primary analysis sample. The Duke Uni-
versity institutional review board approved the study and
waived patient consent.
We leveraged Duke’s Enterprise Data Unified Content
Explorer (DEDUCE), a Web-based data query tool, to
Abbreviation
and Acronym
RCT  randomized clinical
trial
ary Outcome Setting* Size >6 Months† <$20‡ IT§ Sponsor
CE H 10,848    I
bined clinical H 7,138    I
p/mortality O 7,041    I
/weight H 200    G
ll-being/Cr H 300    G
ical status O 250    G
CE H 18,141    I
p/mortality O 2,600    I
k O2 uptake O 190    G
rct size H 210    G
cystatin C H 360    G
ety H 500    I
CE O 15,500    I
CE H 12,946    I
ina exam H 200    I
patient compensation for trial participation. §Intensive trial-related testing (IT), defined as cardiac
e measurement during exercise.
matory; APPRAISE-2  Apixaban for Prevention of Acute Ischemic Events 2; ASCEND-HF  Acute
OSPHERE  Aliskiren Trial of Minimizing Outcomes for Patients with Heart failure; CAD  coronary
tinine; Cr  change in creatinine; DOSE  Diuretic Optimization Strategies Evaluation; EXACT-HF 
ent; H  hospital; HF-PEF  heart failure with preserved ejection fraction; Hosp  hospitalization;
venous; MACE  major adverse cardiac events; minus symbol ()  no; NCT ID  national clinical
bol ()  yes; PO  per os; Pop.  population; RED-HF  Reduction of Events With Darbepoetin
Capacity in Diastolic Heart Failure; REVEAL  Reduction of Infarct Expansion and Ventricular
egies Evaluation in Acute Heart Failure; SC  subcutaneous; sHF  systolic heart failure; SOLSTICE 
sclerotic Plaque by Initiation of Darapladib Therapy; STEMI  ST-segment elevation myocardial
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Barriers to Patient Participation in Trials February 19, 2013:762–9standardize and streamline electronic medical chart review
for the sociodemographic and clinical patient factors dis-
played in Table 2. Three variables (language, insurance,
mployment) were not available and were extracted in a
imilar electronic manner from Duke’s Decision Support
epository. After this step, language data were not available
or 71 patients; therefore, we performed a manual review of
he medical charts and screening logs to assess for evidence
f limited English proficiency.
Several variables were derived from patients’ home postal
ddresses. We derived driving distance and driving time by
eferencing patients’ home addresses to the address of Duke




















Education, % by ZIP code, mean‡
Did not graduate high school
High school graduate
Bachelor’s degree
Income, $1,000s by ZIP code‡











1 outpatient encounters in the last year
No. of outpatient encounters
Duke cardiologist
No. of cardiology encounters
Values are median (interquartile range) or n (%). *Self-designated; “ot
Hispanic patients in primary analysis sample. †Missing data for 23 pa
Census 2000 education and income data for certain ZIP codes. §Calcu
International Classification of Diseases 9th Revision diagnosis (codes 2
as well as more severe disorders) preceding the screening date.
IQR  interquartile range; RCT  randomized clinical trial.niversity Medical Center using CDX Technologies Zip-Stream (Randolph, New Jersey) integrated with Microsoft
MapPoint and Excel (Redmond, Washington). Crosscheck
with Google maps (Mountain View, California) showed
similar driving distances and times. Based on patients’ home
ZIP codes, we assigned population representative values for
educational attainment, median income, and rural versus
urban residence using U.S. Census Bureau 2000 data (31).
Definitions. Our main outcome measure, namely, not
participating in a RCT, was defined as a patient not
enrolling in any of the RCTs for which he or she was
screened. Definitions of patient- and trial-specific factors





(n  377) p Value
55.3–75.5) 61.3 (53.5–70.2) 0.001
59.4) 263 (69.8) 0.006
40.7) 114 (30.2)
65.8) 215 (57.0)
31.7) 145 (38.5) 0.06
2.5) 17 (4.5)
56.1) 206 (54.6) 0.94
86.7) 334 (88.6) 0.47
23.7) 103 (27.3) 0.32
17.3) 68 (18.0)






32.8–41.7) 38.5 (31.7–41.7) 1.00
71.2) 253 (67.1) 0.27
13.3) 29 (7.7) 0.03
10.9–58.2) 35.1 (10.6–67.2) 0.34
22.4–90.8) 52.1 (23.4–102.6) 0.48
1–4) 3 (1–6) 0.02
46.8) 199 (52.8) 0.13
35.6) 115 (30.5)
45.7) 171 (45.4) 0.18
18.7) 91 (24.1)
70.9) 292 (77.5) 0.06
0–10) 6 (1–15) 0.001
50.4) 249 (66.1) 0.001
0–3) 2 (0–6) 0.001
ce denotes Asian, Native American, or unspecified/unknown race; no
‡Extracted by ZIP code; missing data for 26 patients due to missing
rom patient home address to trial center address. Any mental health
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February 19, 2013:762–9 Barriers to Patient Participation in TrialsStatistical analyses. We stratified the primary analysis
ample into those who participated and those who did not
articipate in a RCT. Demographic, clinical, and trial
haracteristics were compared across groups. Continuous
ariables are presented as median (interquartile range).
ategorical variables are expressed as frequency percentages.
nivariable analysis was performed using the Wilcoxon
ank-sum test and Fisher’s exact test for continuous and
ategorical variables, respectively.
Our main outcome measure occurred commonly; there-
ore, we used a modified Poisson regression model with a
obust error variance (32) to identify the factors that were
ndependently associated with not participating. Relative
isks with 95% confidence intervals were calculated to
xamine the adjusted associations. Variables were selected
or multivariable analysis based on clinically judged a priori
mportance and based on differences between the groups in
nivariable comparisons. Patient-specific variables in the
odel were age, sex, race, out-of-state residence, hospital
dmission, Charlson Index, and Duke cardiologist. Trial-
pecific variables were intensive trial-related testing, antici-
ated trial participation 6 months, and trial sponsor
(industry versus government). The relationship between age
and not participating was nonlinear; therefore, we used
linear spline transformation with 1 knot at age 65 years, and
the associations of increases in age with not participating
were interpreted before and after 65 years of age. For
modeling, Charlson Index scores were categorized into
tertiles (0 to 1, 2 to 3, and 4 to 15). No covariate data were
missing in the multivariable analysis.
We performed tests for interaction between age and sex
on the basis of a prior report of such an interaction in heart
failure trial participation (6). We also performed tests for
interaction between independent risk factors with chi-
square values 10. To facilitate the interpretability of the
esults, age was considered as a dichotomous variable (65
years old vs. 65 years old) in the interaction analyses. We
also performed a sensitivity analysis in which we excluded
126 patients who were perceived by the trial team to have
barriers to participation after reviewing the medical chart,
speaking with the clinical providers, or interviewing the
patient or the patient’s family. This included patients with
altered mental status, clinical instability, a history of or
perceived risk for nonadherence, substance abuse, or cases in
which the provider declined. In these cases, there was
concern that the patients may have been unable to provide
informed consent or were unable to follow trial protocols,
and decisions regarding participation were largely made by
persons other than the patient. We also performed a
sensitivity analysis in which we excluded the 139 patients
who were considered for multiple trials to assess whether
our results were dependent on the coding scheme used for
patients who were screened for multiple trials.
Statistical analyses were performed using SAS version 9.2
(SAS Institute, Cary, North Carolina). All p values are2-sided with an alpha level of 0.05. No adjustments were
made for multiple comparisons.
Results
Patient-specific factors. In the primary analysis sample,
the median age was 63 years (interquartile range: 54 years to
72 years), 35% were women, and the median Charlson
Index was 2 (interquartile range: 1 to 5). Patients who did
not participate in a RCT represented 42% of the sample.
Compared with RCT participants, those not participating
were older and more commonly women, but similar in race
and ethnicity (Table 2). Clinically, nonparticipants had a
modestly lower comorbidity burden, and similar rates of any
broadly defined mental health diagnosis and hospital admis-
sions in the prior year. Participants had more frequent
outpatient medical contact (overall and cardiology) at the
study institution relative to those who did not participate.
There were no significant differences in marital status,
religion, insurance status, employment, and ZIP code as-
signed educational attainment, income levels, or urban
living.
Persons who did not participate were more likely to reside
out-of-state, but had similar overall driving time and dis-
tance compared with persons who participated. Specifically
examining the subgroup of patients who did not participate
and stated that travel distance was the primary reason for
not participating (n  22), median driving distance was
143 miles (interquartile range: 82 to 241 miles), and
median driving time was 196 min (interquartile range:
150 to 277 min).
Trial-specific factors. Table 3 shows the prevalence of
trial-specific factors stratified by participation status. More
patients who did not participate were considered for trials
with intensive trial-related testing, an anticipated participa-
tion of 6 months, industry sponsorship, and size of
1,000 participants. A smaller proportion of patients who
did not participate were considered for trials that offered
$20 in total compensation or recruited in the outpatient
setting.







(n  377) p Value
Intensive trial-related testing* 134 (48.2) 48 (12.7) 0.001
Trial participation 6 months 244 (87.8) 162 (43.0) 0.001
Industry trial sponsor 252 (90.7) 227 (60.2) 0.001
Size 1,000 subjects 158 (56.8) 169 (44.8) 0.003
Total compensation $20 32 (11.5) 131 (34.8) 0.001
Outpatient recruitment 43 (15.5) 115 (30.5) 0.001
Values are n (%). *Intensive trial-related testing was defined as cardiac magnetic resonance
imaging, retinal examinations requiring extended study visits, and peak oxygen uptake measure-
ment during exercise.
RCT  randomized clinical trial.
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in a RCT. In multivariable regression, intensive trial-
related testing, longer trial length, and older age after 65
years were the 3 factors most strongly associated with not
participating in a RCT (Fig. 1). Out-of-state residence
and female sex were also independent factors. There was
no independent association of participation status with
industry sponsorship, Charlson Index, number of admis-
sions, Duke cardiologist, race, or increased age before age
65 years. The C-Index for the model was 0.85.
Reasons for not participating. For the 278 patients who
did not participate in a RCT, the primary reasons are
categorized in Figure 2. The 4 most frequently used
individual categories were unspecified reason for decline of
participation, clinical instability, a history of or perceived
risk for nonadherence, and patient-perceived travel bar-
riers (distance or transportation), accounting for approx-
imately two-thirds of the reasons for not participating.
Travel barriers were especially common in patients who
were considered for lengthier trials and among the elderly
(Online Results).
Supplemental analyses. Sensitivity, interaction, and sub-
group analyses (Online Results) were largely consistent with
our primary results. In sensitivity analyses (Online Figs. 1
Figure 1 Multivariable Analysis of Factors Associated With Not
The multivariable model included all of the factors in the Forest plot. Factors are o
fidence intervals (CI) are presented. The analysis included the primary analysis sa
defined as cardiac magnetic resonance imaging, retinal examinations requiring ext
comorbidity burden was quantified by the Charlson Index. Hospital admissions we
patient encounter within the past year with a Duke University Medical Center-affiliaand 2), the 3 factors most strongly associated with notparticipating in a RCT remained intensive trial-related
testing, longer trial length, and older age after 65 years.
Discussion
Trial-specific factors were more strongly associated with not
participating in RCTs than patient-specific factors in our
study, which is unique in the granularity of patient- and
trial-specific factors simultaneously considered. Two trial-
specific factors, intensive trial-related testing and an antic-
ipated participation of 6 months, were most strongly
linked with lack of participation. Patient-specific factors
that were independently associated with not participating
included older age after 65 years, female sex, and out-of-
state residence.
Under-participation in RCTs: a longstanding systemic
challenge in the United States. Between 1997 and 2009,
U.S. federally funded RCTs of coronary artery disease
populations required 50% enrollment abroad (3). The
United States is not alone in its recruitment problems:
among 114 trials in the United Kingdom conducted be-
tween 1994 and 2002, 2 in 3 failed to recruit the target
sample size within the planned time period (2). Slow or
incomplete enrollment can undermine trial completion,
statistical power, and the timely availability of results to
icipating in a Cardiovascular Randomized Clinical Trial
from top to bottom by highest to lowest chi-square. Relative risks and 95% con-
f 655 subjects without a language barrier. Intensive trial-related testing was
study visits, or peak oxygen uptake measurement during exercise. Chronic






ted caguide clinical practice, and adds expense, limiting funding
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site and sponsor interest in future RCTs.
Beyond impeding trial operations, under-representation
of certain community patient groups in RCTs challenges
the generalizability of the trial results. We are approaching
the 2-decade mark since the National Institutes of Health
Revitalization Act called for greater representation of
women and minorities in RCTs (5). Under-representation
of women has been shown in a number of studies (5–13),
with women comprising only 27% on average of the
participants in cardiovascular RCTs (9,13) and National
Institutes of Health initiatives failing thus far to improve on
this (9). In our study, female sex was independently associ-
ated with not participating in cardiovascular RCTs, yet
interestingly, race was not. Although the elderly were not
a focus group of the Revitalization Act, or national
guidelines on inclusiveness in clinical trials that followed
in 1994 (11), we found that older age was a risk factor for
not participating in a RCT, independent of comorbidi-
ties. Patients with limited English proficiency represent
another vulnerable group that was systematically excluded
from RCT participation in our study because of the lack
of necessary resources for native language communica-
tion. There is wide variability across institutions in the
availability of such resources, although a case can be made
for greater resource allocation to support consistent
inclusion of this growing segment of the population in
Figure 2 Distribution of Primary Reasons for Not Participating
In the 278 subjects without a language barrier who did not participate in a trial, th
factors, and patient perceptions. Within these groups, the bar plots show the perc
sons for not participating, as documented in the screening logs. Altered mental st
son for decline of participation was identified. Travel barrier included travel distancclinical research (14).Patient factors and provider perceptions as barriers to
RCT participation. Among patient-reported reasons for
not participating in RCTs, inconvenience and inability to
complete study requirements are common themes. In tar-
geted interviews conducted during an earlier study from our
institution (33), 27% of patients cited inconvenience as their
primary reason for deciding against RCT enrollment. In our
study, travel distance and difficulty arranging transportation
clustered in patients who were considered for longer trials
and in the elderly. The inconvenience of in-person visits
likely reaches beyond travel distance and transportation
arrangements alone; for example, in women especially,
there may be the need to arrange child care to attend a
study visit (15).
Many patients in our study did not provide specific
reasons for declining RCT participation, suggesting that
patients are often not transparent in their attitudes toward
RCTs in practice. Patient fear of random assignment to
treatment (decision made by “the computer”) and research
risks, engrained with elements of mistrust, present formi-
dable challenges in RCT recruitment (33). In women,
particularly, the perceived risk of harm from research has
been linked to reluctance to participate in RCTs (34,35).
Given that public exposure to research may be skewed by
sensational media reports of error or duplicity, a continuing
mission of the research community is to provide a more
balanced perspective by raising awareness regarding the
robust mechanisms in place to protect human research
ardiovascular Randomized Clinical Trial
ary reasons for not participating were grouped into trial team perceptions, mixed
e of patients who were contained within the selected categories of primary rea-
cludes dementia and delirium. Unspecified decline indicates that no specific rea-




e andsubjects and ensuring that they are implemented.
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patient may play a primary role in the participation out-
come, including perceptions regarding adherence, substance
use, clinical status, or other factors, which together ac-
counted for 45% of patients who did not participate in a
RCT in our sample. Limiting enrollment of such patients,
who may be less likely to adhere to the study protocol, is an
important consideration in many RCTs. However, it is
important to note that barriers to RCT participation per-
ceived by the trial team and providers are often based on
overall impressions rather than formal criteria, and their
importance varies based on trial follow-up requirements.
Ultimately, targeting these issues in future RCTs may
promote more balanced representation of patient subgroups
and strengthen the efforts of the American College of
Cardiology’s Coalition to Reduce Disparities in Cardiovas-
cular Care and Outcomes (CREDO) group aimed at
achieving equitable care and outcomes for all patients,
regardless of race, ethnicity, sex, and age (36).
Implications for future clinical trial design and conduct.
Given our results, it is important for the clinical trial
community to consider whether a study question could be
reliably answered with less intensive testing or through a
study of shorter duration. If this is not possible, minimizing
inconvenient in-person visits could potentially improve
participation. For example, a recently launched longitudinal
study is using centralized follow-up telephone interviews
instead of multiple patient trips to the research center (37).
In the modern era, creative follow-up solutions can be
explored; for example, patients may directly interact via
Internet and mobile technologies to efficiently and conve-
niently provide follow-up information.
Practical solutions to trial design and conduct that inte-
grate the research enterprise with clinical care and medical
education will likely be most successful. For instance, using
trial activities as a venue to provide clinical information to
patients, providers, and community members enhances
health care quality in real time (36). Informatics systems
that integrate trial data with existing electronic medical
records could augment the availability of patient informa-
tion at the point of care while increasing the efficiency of
research data collection. Such integration may allow for
efficient tracking of patient status and reassessment of trial
candidacy after clinical stabilization, as well as more objec-
tive identification of likely nonadherent patients (e.g., no-
show rate for outpatient appointments). A further advan-
tage of informatics systems that bridge the clinical and
research enterprises is the increased ability to expose and
engage physicians early in their medical education to clinical
research. In appropriate circumstances, research participa-
tion might become part of routine care (38) or random-
ization may be clustered at the site level (39) to alleviate
the burden of additional work associated with informed
consent.
Study limitations. First, our study setting was a single
academic medical center in the southeastern United Stateswith a high volume of cardiovascular RCT research, and we
explored only participation in cardiovascular RCTs. There-
fore, our results may not be generalizable to other institu-
tions in other locations in the United States or abroad or to
participation in RCTs in other therapeutic areas. Second, all
patients in our study had access to a RCT; we did not
address challenges to enrollment at the provider level (i.e.,
providers as gatekeepers). Third, this was an observational
study, precluding direct assessment of causality, and unmea-
sured confounders are possible in this observational analysis.
Fourth, regarding variables themselves, educational attain-
ment and income were based on population representative
levels according to ZIP code as opposed to direct report by
patients.
Conclusions
Among patients presenting to a high-volume academic
medical center in the southeastern United States who were
considered potentially eligible for RCT participation after
an initial screen against medical eligibility criteria, we
identified multiple potentially actionable barriers to partic-
ipation. While age, sex, and state of residence were associ-
ated with not participating, longer trial duration and inten-
sive testing were the factors most significantly related to
RCT participation. One major implication of our study is
the need for innovative RCT designs using integrative
approaches and emerging technologies to foster convenience
and thereby facilitate greater RCT participation.
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